Telix Pharmaceuticals (TLX) Equity Ratio (2023 - 2024)
Telix Pharmaceuticals (TLX) reported Equity Ratio of 0.37 for Q4 2024, up 2.15% year-over-year from 0.37 in Q1 2024, and up 2.15% quarter-over-quarter from 0.37 in Q4 2023.
Telix Pharmaceuticals (TLX) Equity Ratio (2023 - 2024) Analysis & Trends
Telix Pharmaceuticals (TLX) has 2 years of Equity Ratio data on file, last reported at 0.37 in Q4 2024.
- Equity Ratio for Q4 2024 came in at 0.37, up 2.15% year-over-year; the trailing twelve-month figure through Dec 2024 was 0.37 (up 2.15% YoY), and the FY2024 annual result was 0.37, up 2.15% from the prior year.
- Equity Ratio improved to 0.37 in Q4 2024 per TLX's latest filing, from 0.37 in the prior quarter.
- Over five years, Equity Ratio peaked at 0.37 in Q4 2024 and troughed at 0.37 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 191.07 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.98 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 0.04 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.42 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.73 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 0.79 |
| 10 | Telix Pharmaceuticals | 4.81 Bn | 4.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.37 |
| Dec 31, 2023 | 0.37 |